Client News

OKYO Pharma Limited: Corporate Presentation
Home / Client News / OKYO Pharma Limited: Corporate Presentation

London and New York, NY, February 21, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation  entitled: “A Lipidated Protease-Resistant Chemerin Peptide Offers a Novel Therapeutic for Dry Eyes” on February 22, 2023 at the 2nd Annual GPCRs-Targeted Drug Discovery Summit at the Hyatt Regency in Boston, MA. Dr. Jacob’s talk, which is scheduled for the afternoon of February 22, will cover the planned clinical development of OKYO’s drug candidate OK-101 to treat dry eye disease (DED).



If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This